Notice2022-22476
Prospective Grant of Exclusive Patent License: Radiotherapeutics for Nasopharyngeal Cancer
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 17, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Molecular Targeting Technologies, Inc. (MTTI); a Delaware corporation, with its principle place of business in West Chester, Pennsylvania, to practice the inventions embodied in the issued patents and patent applications listed in the Supplementary Information section of this notice.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 199 (Monday, October 17, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 199 (Monday, October 17, 2022)]
[Notices]
[Pages 62866-62867]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-22476]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Radiotherapeutics
for Nasopharyngeal Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Heart, Lung and Blood Institute (NHLBI), National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an exclusive patent license to Molecular
Targeting Technologies, Inc. (MTTI); a Delaware corporation, with its
principle place of business in West Chester, Pennsylvania, to practice
the inventions embodied in the issued patents and patent applications
listed in the Supplementary Information section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the NHLBI Office of Technology Transfer and Development
November 1, 2022 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Michael Davis, JD, Ph.D., Deputy Director, NHLBI
OTTAD, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479,
phone number 301-451-9032, or <a href="/cdn-cgi/l/email-protection#88e5e1ebe0e9ede4a6ece9fee1fbbcc8e6e1e0a6efe7fe"><span class="__cf_email__" data-cfemail="6a070309020b0f06440e0b1c03195e2a040302440d051c">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement to MTTI:
--------------------------------------------------------------------------------------------------------------------------------------------------------
Patent No. or patent
NIH Ref No. application No. Issue date Filing date Title
--------------------------------------------------------------------------------------------------------------------------------------------------------
E-150-2016-0-US-01................ 62/333,427........... ................................ May 9, 2019..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-PCT-02............... PCT/US2017/031696.... ................................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-CN-03................ 201780029003X........ ................................ November 9, 2018................ Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-EP-04................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-JP-05................ 2018-558662.......... TBD (Allowed)................... May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-US-06................ 10,696,637........... June 30, 2020................... May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-SG-07................ 11201809982R......... November 8, 2021................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-CH-08................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-DE-09................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
(Certificate No. Evans Blue Derivatives
602017027023.7). and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-FR-10................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
[[Page 62867]]
E-150-2016-0-GB-11................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-IE-12................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-IT-13................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-1-PCT-01............... PCT/US2017/054863.... ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-CN-02................ 201780095506.7....... ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-EP-03................ 17928082.1........... ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-JP-04................ 2020-519137.......... ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-SG-05................ 112020002882V........ ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-US-06................ 10,981,866........... April 20, 2021.................. October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-HK-07................ 62020015610.2........ ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
--------------------------------------------------------------------------------------------------------------------------------------------------------
The patent rights in these inventions have been assigned to the
Government of the United States of America. The prospective patent
license may be granted in a field of use directed to radiotherapeutics
for nasopharyngeal cancer and the extent of the exclusive license may
be territorially restricted to the United States, its Territories,
Commonwealths and Possessions; and Asia.
The invention pertains to a radiotherapeutics against cancers that
express somatostatin receptor. Radionuclide therapy directed against
tumors that express somatostatin receptors (SSTRs) has proven effective
for the treatment of advanced, low- to intermediate-grade
neuroendocrine tumors. The subject radiotherapeutic covered by the
patent estate includes a somatostatin (SST) peptide derivative like
octreotate (TATE), conjugated to an Evans Blue (EB) analog, and further
chelated via DOTA to therapeutic radionuclide \177\Lu, a beta emitter.
The EB analog reversibly binds to circulating serum albumin and
improves the pharmacokinetics of SST peptide derivatives and reduce
peptide-receptor radionuclide therapy toxicity. EB analog conjugated to
octreotate (EB-TATE) has been shown by the inventors to provide
reversible albumin binding in vivo and extended half-life in
circulation. When EB-TATE is slowly released into the tumor
microenvironment, tumor uptake and internalization into SSTR positive
tumors resulted in delivery of radioactive particles and tumor cell
killing. EB-TATE displayed significantly more favorable
pharmacokinetics than TATE alone by achieving higher tumor to non-tumor
penetration as evidenced by positron emission tomography.
Complete applications for a license in the prospective field of use
that are timely filed in response to this notice will be treated as
objections to the grant of the contemplated exclusive patent license.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Michael D. Davis,
Deputy Director, National Heart, Lung, and Blood Institute, Office of
Technology Transfer and Development.
[FR Doc. 2022-22476 Filed 10-14-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 17, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.